Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Oncofertility
  • Reduced price
The ESC Textbook of Thrombosis

The ESC Textbook of Thrombosis

9780192869227
982.80 zł
884.52 zł Save 98.28 zł Tax included
Lowest price within 30 days before promotion: 884.52 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
The ESC Textbook of Thrombosis is the third iteration of Therapeutic Advances in Thrombosis. Now a new addition to the European Society of Cardiology (ESC) publications portfolio, it is informed by the work of the ESCs Working Group on Thrombosis. Written by internationally renowned experts in the field of thrombosis, the textbook presents an up-to-date and in-depth review of all aspects of thrombosis and antithrombotic therapies. Not only does it reflect contemporary European guidelines from the ESC but also it also summarizes the latest evidence from clinical trials. Covering the topic in great detail with thirty-one chapters, the textbook is split into four sections:: Pathophysiology of thrombosis, Clinical pharmacology of antithrombotic drugs, Therapeutic strategies, and Special situations. Appealing to the large community of cardiovascular healthcare specialists in Europe and across the world, the textbook is a must read for cardiologists dealing with acute and chronic coronary syndromes, atrial fibrillation, artificial heart valves and pulmonary embolism. It will also appeal to cardiac surgeons, cardiovascular researchers, and general physicians alike.
Product Details
OUP Oxford
102213
9780192869227
9780192869227

Data sheet

Publication date
2023
Issue number
1
Cover
hard cover
Pages count
400
Dimensions (mm)
219 x 276
Weight (g)
1218
  • Introduction; Section 1: Pathophysiology of thrombosis; Arterial thrombosis: Pathophysiological background; Venous thrombosis and thromboembolism: Pathophysiological background; Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background; Thrombosis on foreign surfaces and devices; Section 2: Clinical pharmacology of antithrombotic drugs; Aspirin; Platelet P2Y12 inhibitors; Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists; Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid; Vitamin K antagonists; Dabigatran; Oral factor Xa (FXa) inhibitors; Forthcoming oral factor XIa and FXIIa inhibitors; Thrombolytic therapy and ancillary antithrombotic therapies; Section 3: Therapeutic strategies; Antithrombotic strategies in primary cardiovascular prevention; Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions; Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes; Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions; Antithrombotic therapies in ischaemic stroke; Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis; Atrial fibrillation: current and forthcoming antithrombotic therapies; Venous thromboembolism: prophylaxis and treatment; Biomarker-based risk stratification in cardiovascular disease; Section 4: Special situations; Antithrombotic therapies in inherited or acquired thrombophilia; Prevention and treatment of bleeding related to antithrombotic drug treatment; Management of patients treated with antithrombotic drugs undergoing surgery; Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome; Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy; Antithrombotic agents and drug-drug interactions; Personalised antithrombotic therapy: Measuring individual variation and monitoring; Drug development, clinical trials, and regulatory requirements;
You might also like
Comments (0)

  • Frequently purchased together

    No products available